The reported elevation of neurodegenerative biomarkers (e.g., glial fibrillary acidic protein GFAP, neurofilament light chain-NFL, tau proteins) or, conversely, the decreased levels of neuroprotective markers following COVID-19 infection lends further evidence to the connection between SARS-CoV-2 infection and neurodegenerative disease onset [105]. This evidence concerns the gene GFAP and neurodegenerative disease.